Skip to main content
. Author manuscript; available in PMC: 2011 May 9.
Published in final edited form as: Urol Oncol. 2009 JAN-FEB;27(1):53–63. doi: 10.1016/j.urolonc.2008.07.036

Figure 1. The effects of long term treatment with letrozole on the growth of MCF-7Ca xenografts.

Figure 1

A) Animals were inoculated with MCF-7Ca cells at two sites on each flank and were supplemented with androstenedione (100 mg/day) for the duration of experiment [75]. When the tumors reached a measurable size (∼300 mm3), animals were assigned to 3 groups (n = 20 per group), and injected sc daily with vehicle (control), or tamoxifen (100 mg/day), or letrozole (10 mg/day). Tumor volumes were measured weekly and were expressed as the percent change relative to the initial tumor volume. Two mice per group were sacrificed and tumors were collected for analysis at 4, 28, and 56 weeks as indicated on the graph. B) The effect of letrozole treatment on Her-2, p-Shc, Shc, Grb2, p-MAPK, MAPK, ER-a, p-ER-a and PgR expression in MCF-7Ca tumor xenografts [75]. Letrozole treated tumors collected at 4 weeks, 28 and 56 weeks (above), were analyzed by Western immunoblotting, and were compared to vehicle treated tumors collected at Week 4 (control). Tumors were homogenized in lysis buffer as described previously [75].